Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Isabelle Solomon"'
Autor:
Dima Yackoubov, Ronit Simantov, Yona Geffen, Avishay Edri, Avner Yeffet, Isabelle Solomon, Moriya Gamliel, Yaron Meirow, Eliran Arbib, Yael Yoffe-Mizrahi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/3d576a14fc024d0a90f18e5b44b323f8
Autor:
Yael Yoffe-Mizrahi, Moriya Gamliel, Isabelle Solomon, Sireen Seed, Avner Yeffet, Yaron Meirow, Eliran Arbib, Dima Yackoubov, Rivka Shlomai, Roei Mazor, Eyal Shoshani, Ronit Simantov, Yona Geffen
Publikováno v:
Transplantation and Cellular Therapy. 29:S159
Autor:
Johannes Sam, Dafne Franz Demane, Estelle Marrer-Berger, Mariana Werner Sunderland, Christophe Boetsch, Dimitrios Zervas, Anne Goubier, Jake Y. Henry, Teresa Marafioti, Chen Qing, Jan Eckmann, Frederick Arce Vargas, Reto Flury, Sara Belli, Hans Koll, Ayse Akarca, Maria Amann, Bjoern Jacobsen, Lea Leibrock, Anna Śledzińska, Roger Sutmuller, Sergio A. Quezada, Josephine Salimu, Joerg Benz, Claudio Murgia, Isabelle Solomon, Joanne Ruth Clancy, Mark Adrian Brown, Karl S. Peggs, Pascal Merchiers, Ehsan Ghorani, Andrew Georgiou
Publikováno v:
Nature Cancer. 1:1153-1166
Intratumoral regulatory T (Treg) cell abundance associates with diminished antitumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high-affinity receptor subunit for interleukin (IL)-2, is a selective target fo
Autor:
Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristobal Costoya, Dafne Franz Demane, Mansi Shah, Eyal David, Chamutal Borenstein, Oren Barboy, Ignacio Matos, Karl S. Peggs, Sergio A. Quezada, Ido Amit
Publikováno v:
Nature Cancer. 3:1404-1404
Autor:
Ido Yofe, Tomer Landsberger, Adam Yalin, Isabelle Solomon, Cristobal Costoya, Dafne Franz Demane, Mansi Shah, Eyal David, Chamutal Borenstein, Oren Barboy, Ignacio Matos, Karl S. Peggs, Sergio A. Quezada, Ido Amit
Publikováno v:
Nature cancer. 3(11)
Despite the clinical success of checkpoint inhibitors, a substantial gap still exists in our understanding of their mechanism of action. While antibodies to cytotoxic T lymphocyte-associated protein-4 (CTLA-4) were developed to block inhibitory signa
Autor:
Isabelle, Solomon, Maria, Amann, Anne, Goubier, Frederick, Arce Vargas, Dimitrios, Zervas, Chen, Qing, Jake Y, Henry, Ehsan, Ghorani, Ayse U, Akarca, Teresa, Marafioti, Anna, Śledzińska, Mariana, Werner Sunderland, Dafne, Franz Demane, Joanne Ruth, Clancy, Andrew, Georgiou, Josephine, Salimu, Pascal, Merchiers, Mark Adrian, Brown, Reto, Flury, Jan, Eckmann, Claudio, Murgia, Johannes, Sam, Bjoern, Jacobsen, Estelle, Marrer-Berger, Christophe, Boetsch, Sara, Belli, Lea, Leibrock, Joerg, Benz, Hans, Koll, Roger, Sutmuller, Karl S, Peggs, Sergio A, Quezada
Publikováno v:
Nature cancer. 1(12)
Intratumoral regulatory T cell (Treg) abundance associates with diminished anti-tumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high affinity receptor subunit for IL-2, is a selective target for Treg deplet
Autor:
Felipe Gálvez-Cancino, Sergio A. Quezada, Karl S. Peggs, Ehsan Ghorani, Frederick Arce Vargas, Chen Qing, Isabelle Solomon
Publikováno v:
E-Poster Presentations.
Background Regulatory T cell (Treg) depletion with antibodies against CD25 is effective in tumor models but response rates are low in poorly infiltrated B16 melanomas. Combination with a tumor vaccine enhances efficacy, but relapse usually occurs fol
Autor:
Gabriel Schnetzler, Jan Eckmann, Sergio A. Quezada, Estelle Marrer-Berger, Roger Sutmuller, Kolben Theresa, Christophe Boetsch, Sara Belli, Mark Brown, Johannes Sam, Dimitrios Zervas, Maria Amann, Frederic Arce Vargas, Chen Qing, Vaios Karanikas, Sebastian Neumann, Reto Flury, Anne Goubier, Karl S. Peggs, Hans Koll, Isabelle Solomon, Claudio Murgia, Josephine Salimu
Publikováno v:
Cancer Research. 80:4553-4553
Despite the advances in cancer immunotherapy, in particular in the field of checkpoint inhibitors (CPI), many patients fail to respond (primary resistance) or initially benefit but then progress upon treatment (secondary resistance). High regulatory
Autor:
Dafne Sofia Franz Demane, Kroopa Joshi, Cristóbal Costoya, Dimitrios Zervas, Isabelle Solomon, Karl S. Peggs, Sergio A. Quezada
Publikováno v:
The Journal of Immunology. 204:169.29-169.29
Inducible T cell co-stimulator (ICOS) is a co-stimulatory receptor expressed on tumor infiltrating regulatory and effector T cells. ICOS potential role in cancer control is supported by the correlation between ipilimumab’s efficacy and the presence
Autor:
Karl S. Peggs, Adam Jelinski, Sergio A. Quezada, Isabelle Solomon, Marc Robert de Massy, Tomer Landsberger, Ido Yofe, Ido Amit
Publikováno v:
Cancer Immunology Research. 8:A101-A101
Immunotherapies have revolutionized and continue to revolutionize cancer patient care; however, much of our understanding of the mechanism of action of these therapies is currently limited. The accumulation of regulatory T cells (Tregs) in the tumor